A Phase lll Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral03/06/2014 - 03/05/2017 (PI)
PaxVax, Inc.
A Phase lll Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX020011/01/2013 - 10/31/2016 (PI)
PaxVax, Inc.
A Multicenter, randomized, observer-blinded, active-controlled study evaluating the safety, tolerability pharmacokinetics an efficacy of ceftaroline versus cetriaxone in pediatric subjects with compli01/01/2013 - 06/30/2015 (PI)
Cerexa, Inc.
A multi-center, randomized, observer-blinded, active-controlled study evaluating the safety, tolerability, pharmacokinetics and efficacy of ceftaroline versus cetriaxone plus vancomycin in pediatric10/01/2012 - 09/30/2013 (PI)
Cerexa, Inc.
Long Term Immunity and Safety following Vaccination with the Japanese Ecephalitis Vaccine IC51 in a Pediatric Population in Non-endemic Countries12/12/2011 - 12/11/2012 (PI)
Intercell AG
IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO, JESPECT) IN A PEDIATRIC POPULATION IN NON-ENDEMIC COUNTRIES. UNCONTROLLED, OPEN-LABEL PHASE 3 STUDY02/01/2010 - 06/30/2012 (PI)
Intercell AG
Evaluation of Impact of Antimicrobial Therapy on Carriage of Susceptible and Resistant Streptococcus Pneumoniae09/01/1999 - 06/30/2004 (PI)
SmithKline Beecham
Use of Intrapulmonary Percussive Ventilation to Prevent Respiratory Disease in Adolescents with Impaired Pulmonary Function09/01/1999 - 08/31/2000 (PI)
Deborah Munroe Noonan Memorial Fund Medical Fdn Inc
Safety of Simultaneous versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Inactivated Influenza Vaccine (IIV4) in Pregnant People (Contributing)09/28/2023 - 09/27/2028 (PI)
Centers for Disease Control and Prevention/DHHS
CISA Clinical Vaccine Safety Evaluation Boston Contributing Tasks 1 and 209/28/2023 - 09/27/2028 (PI)
Centers for Disease Control and Prevention/DHHS
217715 (MMRVNS 20-001)12/06/2023 - 12/06/2026 (PI)
GlaxoSmithKline
A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Relative Safety, Tolerability, Efficacy, and Immunogenicity of a Modified RNA Vaccine against Influenza Compared to a Licensed Inactivated Influenza Vaccine in Healthy Adults Greater than or Eq11/11/2022 - 11/11/2025 (PI)
Pfizer, Inc
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA-BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN (Pfizer C4591048)09/23/2022 - 09/23/2025 (PI)
Pfizer, Inc
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALT03/08/2021 - 03/08/2025 (PI)
Pfizer, Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162b2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162b2 (Pfizer C4591031, Protocol Amendment 1, 27 May 2021)07/06/2021 - 12/31/2024 (PI)
Pfizer, Inc
CISA Clinical Vaccine Safety Evaluation Boston Contributing Tasks 1 and 209/29/2022 - 09/28/2024 (Subcontract PI)
PI:
Elizabeth D. Barnett, MDCenters for Disease Control and Prevention/DHHS HHS CDC
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2-RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS05/29/2020 - 12/31/2023 (PI)
Pfizer, Inc
A Phase 3, Randomized, Double- or Observer-Blinded, Placebo Controlled Trial to Evaluate the…03/09/2020 - 12/31/2023 (PI)
Pfizer, Inc
Showing 10 of 23 results.
Show All Results
GeoSentinel Freezer Project11/15/2022 - 11/14/2023 (PI)
International Society of Travel Medicine
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS06/29/2020 - 06/29/2023 (PI)
Pfizer, Inc
A Phase 2b Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women 18 Through 49 Years of Age and Their Infants08/22/2019 - 04/30/2023 (PI)
Pfizer, Inc
ThreeWire BAA/Secondment Agreement10/07/2019 - 12/31/2022 (PI)
ThreeWire Inc.
PXVX-VC-200-00608/24/2017 - 12/31/2022 (PI)
PaxVax, Inc.
Clinical Immunization Safety Assessment (CISA) Project - Clinical Consult Contributing - COVID Funded Portion09/17/2020 - 09/28/2022 (PI)
Centers for Disease Control and Prevention/DHHS
Clinical Immunization Safety Assessment (CISA) Project - Clinical Consult Contributing09/29/2017 - 09/28/2022 (PI)
Centers for Disease Control and Prevention/DHHS
CISA Clinical Evaluation Consult Activity09/29/2013 - 10/01/2020 (PI)
Centers for Disease Control and Prevention/DHHS
Refugee And Immigrant Health P07/01/2000 - 06/30/2020 (PI)
Massachusetts Dept. of Public Health / DPH
FLUAD vs Fluzone High-Dose Study (Contributing)09/29/2016 - 09/28/2019 (PI)
Centers for Disease Control and Prevention/DHHS
Assessing Feasibility and Impact of Implementing an Oral Water Hydration Strategy to Prevent Post…09/15/2014 - 09/14/2016 (PI)
CDC
A Comparison of a rapid enzyme chromatographic screening test for G6PD deficiency with a quantitativ09/19/2006 - 06/30/2012 (PI)
Binax, Inc Dept of Defense
Boston Area Travel Medicine Network (BATMN)09/30/2007 - 09/29/2011 (PI)
CDC5U19CI000508-03